This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2019-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2020
Title: Lixin Lang: Innovator in Therapeutic Compounds
Introduction
Lixin Lang is a notable inventor based in North Potomac, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative therapeutic compounds. With a total of 2 patents, his work focuses on enhancing the efficacy of treatments through novel chemical conjugates.
Latest Patents
Lixin Lang's latest patents include "Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics." This invention is directed to compounds that can be covalently bonded to therapeutic compounds, thereby extending their half-life and improving their effectiveness in treating diseases. Another significant patent is for a "Labeled Evans Blue dye derivative for in vivo serum albumin labeling." This patent outlines a method for blood-pool imaging in mammals, utilizing the disclosed compound for enhanced imaging of lymph nodes.
Career Highlights
Lixin Lang works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His role in this esteemed organization underscores his commitment to advancing healthcare through innovative research and development.
Collaborations
Lixin has collaborated with notable colleagues, including Xiaoyuan Chen and Gang Niu. These partnerships have contributed to the successful development of his patented technologies.
Conclusion
Lixin Lang's contributions to the field of therapeutics through his innovative patents highlight his role as a leading inventor. His work not only advances medical science but also has the potential to significantly improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
